1. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials 
Anthony J. Lembo, Kevin W. Olden, Vanessa Z. Ameen, Susan L. Gordon, Amy T. Heath, Eric G. Carter 
Clinical Gastroenterology and Hepatology 
Volume 2, Issue 8, Pages (August 2004)
DOI: /S (04)

2. Figure 1 IBS characteristics of populations A and B.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (04) )

3. Figure 2 Progression of patients in the study (population A).
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (04) )

4. Figure 3
Percent of days alosetron- or placebo-treated patients in population A experienced satisfactory control of urgency throughout the 12-week treatment and 2-week follow-up phases (∗∗P < 0.003). Insert shows the percent of patients with satisfactory control of urgency during the first week of treatment (∗P < 0.05). •, Alosetron; ○, placebo.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (04) )

5. Figure 4
Proportion of alosetron- or placebo-treated patients in population B with more frequent urgency (i.e., lack of satisfactory control of bowel urgency for ≥10 of 14 days during screening) who improved to ≤1 day of uncontrolled urgency each week during treatment (∗P < 0.01; ∗∗P < 0.001). •, Alosetron; ○, placebo.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (04) )

6. Figure 5
Stool frequency (stools/day) and stool consistency scores at baseline, during treatment, and during follow-up period for alosetron- and placebo-treated patients in population A (∗P < 0.001). •, Alosetron; ○, placebo.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (04) )